Introducing Tabish Waseem, the visionary Chief Executive Officer of AbiCure Sweden AB, a seasoned international business leader driven by a commitment to global excellence. Tabish possesses a robust academic foundation in computer technology, holding a master's degree from KTH. He further honed his business acumen at esteemed institutions such as the Stockholm School of Economics (SSE) and the Stockholm School of Entrepreneurship (SSES).

With an illustrious 14-year career in international business development and sales, Tabish consistently showcases his adeptness at navigating the intricacies of the global market. His impressive track record includes successful product launches in over 40 countries, contributing significantly to business growth. Tabish is a catalyst for growth, excelling in opportunity identification, forging strategic partnerships, and elevating sales to unprecedented levels.

His unwavering commitment to nurturing emerging businesses is underscored by his success in guiding startups through critical growth phases. Boasting practical experience overseeing operations in more than 40 countries, Tabish consistently delivers exceptional results on a global scale.

In his role as CEO of AbiCure Sweden AB, Tabish Waseem spearheads initiatives to revolutionize healthcare in Asia, emphasizing innovation, high quality, and affordability in healthcare products. His remarkable journey and dedication to making healthcare accessible to all have garnered considerable attention and investment interest.

We invite you to join us in supporting Tabish Waseem and the AbiCure team as they embark on a mission to transform healthcare in Asia. Your investment will not only drive the continued success of the company but will also contribute to the availability of quality healthcare in the region.

Invest in the future of quality healthcare for millions alongside AbiCure Sweden AB and become a part of this transformative journey.

Dear Investors,

I trust this message finds you in good health and high spirits.

In my capacity as the Chief Executive Officer of AbiCure Sweden AB, I am delighted to update you on our remarkable journey and the vast opportunities that await us within the Asian healthcare landscape.

AbiCure's inception was driven by a visionary goal – to make superior healthcare products accessible to everyone, irrespective of their financial standing. Today, I am thrilled to announce that we have successfully commenced our mission to realize this vision in Asia. Our unwavering commitment to providing innovative and cost-effective healthcare solutions is gaining traction, and we are eager to share our noteworthy progress with you.

The Asian healthcare market presents a colossal opportunity for our European company. Our esteemed reputation has preceded us, with wide acceptance and respect from healthcare professionals in the region. This solid connection to quality and excellence has firmly established us as a respected healthcare brand among both patients and doctors.

However, the true strength of our venture lies in the vast, untapped potential within the Asian market. With a growing population and an increased focus on healthcare, the business opportunities in Asia are substantial. Our products, bolstered by European quality marks, uniquely position us to leverage these possibilities. The low operational costs in most Asian markets, coupled with the healthy margins our products provide, afford us a significant advantage. This dynamism not only facilitates sales in large volumes but also ensures faster expansion, enhancing the attractiveness of your investment.

Personally, my passion lies in leading AbiCure into new territories across several Asian countries. Following the successful establishment of the Pakistani market, we are now poised to enter the expansive Indian market. India, with its vast population and robust healthcare sector, represents a goldmine of opportunities for AbiCure products. Together, we can make an indelible mark in this extensive arena.

Our team constitutes the bedrock of our success, and I take immense pride in the committed, experienced, and highly competent professionals that form AbiCure. With top-tier qualifications, including individuals with extensive experience from multinational pharmaceutical giants such as Pfizer, AstraZeneca, and GSK, we possess the expertise necessary to guide AbiCure towards a prosperous future.

As we set our sights on the future, our goal is ambitious growth. By January 2024, we aim to achieve a significant milestone by employing a total of 100 individuals, underscoring our commitment to creating employment opportunities, nurturing talent, and expanding our business.

Our journey is nothing short of inspiring, and I extend an invitation for you to become part of our success story. We are seeking investors who share our vision and are ready to embark on this extraordinary journey to revolutionize healthcare in Asia.

In conclusion, I express my sincere gratitude for your attention. AbiCure Sweden AB is on a mission to transform lives, and your support can help us achieve significant milestones. Join us on this exciting adventure, and together, let's build a healthier and more accessible future for Asia, hand in hand.

Thank you for considering this opportunity, and I eagerly anticipate the opportunity to collaborate in shaping a brighter, healthier, and more prosperous future.

Sincerely,

Tabish Waseem
CEO
AbiCure Sweden AB

Invest in AbiCure for:

Thriving Market:

The healthcare sector is flourishing, presenting a consistent rise in demand for groundbreaking solutions. Align your investments with AbiCure Sweden AB to engage in this prosperous market and leverage its vast potential.

Swedish Credibility:

Sweden stands as a reputable figure in the Asian healthcare sector. By investing in AbiCure Sweden AB, you tap into this credibility, paving the way for swift market expansion and growth.

Proven Product Line:

Our portfolio boasts clinically proven healthcare products that have demonstrated enhanced patient outcomes. Investing in AbiCure Sweden AB provides access to a robust foundation of reliable and effective products.

Strategic Focus on the Asian Market:

AbiCure strategically concentrates on the Asian market, identified for its potential for exponential growth. Your investment in AbiCure Sweden AB aligns you with our strategic insights, capitalizing on the escalating demand for healthcare products in Asia.

Committed Team:

Comprising dedicated, ambitious, and experienced professionals, our team is unwaveringly committed to achieving our set objectives. With a wealth of expertise and unwavering commitment, we are poised to navigate challenges and capitalize on opportunities within the healthcare industry.

Investing in AbiCure Sweden AB unlocks the potential for substantial returns in the dynamically evolving healthcare landscape of Asia. Join us on this transformative journey and maximize the impact of your investment.

Key Financial Metrics

Average Cost of Goods 39%

Average Gross Margins 61%

Average Cost of Sales 14%

Average Profit Margin 33%

Timeline for Geographic Expansion in Asia

Embarking on an ambitious journey from 2023 to 2030, AbiCure's Geographic Expansion in Asia unfolds a strategic roadmap. Starting with the launch of sales in Pakistan and the development of AbiCure Vitamin's product line in 2023, the timeline progresses with key milestones. From expanding to new markets and registering pharmaceutical products to introducing high-value items and doubling the team in the Asian branch office, each year marks a purposeful step. The focus extends to India, cardiovascular product portfolios, and continual market additions. This comprehensive plan signifies AbiCure's commitment to global health and wellness, forging a path of impactful expansion throughout the Asian continent.

AbiCure - RoadMap (3)
Swedish PDF
Contact Us

Yearly Financial Report:

Yearly Financial Report 2023